Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib vs Pazopanib plus Gemcitabine in Uterine Leiomyosarcomas
NCT02203760Phase 2Active, not recruiting
- Sponsor
- NOGGO
- Start
- Oct 2019
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib, gemcitabine in uterine leiomyosarcoma (uLMS), uterine carcinosarcoma (UCS), sponsored by NOGGO. Started Oct 2019; status: active, not recruiting.
02
Drugs
pazopanibgemcitabine
03
Conditions
uterine leiomyosarcoma (uLMS)uterine carcinosarcoma (UCS)
Beyond the preview
Go deeper on NCT02203760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02203760.